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Mass antigen testing programs have been challenged because of an alleged insufficient
specificity, leading to a large number of false positives. The objective of this study is to
derive a lower bound of the specificity of the SD Biosensor Standard Q Ag-Test in large
scale practical use.
Methods
Based on county data from the nationwide tests for SARS-CoV-2 in Slovakia between
31.10.–1.11. 2020 we calculate a lower confidence bound for the specificity. As positive test
results were not systematically verified by PCR tests, we base the lower bound on a worst
case assumption, assuming all positives to be false positives.
Results
3,625,332 persons from 79 counties were tested. The lowest positivity rate was observed in
the county of Rožňava where 100 out of 34307 (0.29%) tests were positive. This implies a
test specificity of at least 99.6% (97.5% one-sided lower confidence bound, adjusted for
multiplicity).
Conclusion
The obtained lower bound suggests a higher specificity compared to earlier studies in spite
of the underlying worst case assumption and the application in a mass testing setting. The
actual specificity is expected to exceed 99.6% if the prevalence in the respective regions
was non-negligible at the time of testing. To our knowledge, this estimate constitutes the
first bound obtained from large scale practical use of an antigen test.
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Introduction
While PCR-tests are usually considered as the gold standard to detect infection with the
SARS-CoV-2 coronavirus in terms of sensitivity as well as specificity, antigen tests (Ag-Tests)
offer practical advantages in terms of costs, logistics and speed [1]. Because Ag-Tests may play
a major role in large scale testing strategies [2, 3] in populations with low prevalence, besides
their sensitivity also the specificity is of significant interest, especially as resulting low positive
prognostic values may lead to confusion and public distrust into the testing strategy. The
objective of this study is to obtain a lower bound of the specificity of the SD Biosensor Stan-
dard Q Ag-Test based on data of mass tests in Slovakia and infer Ag-Test specificity from a
large sample of the general population. The lower bound for the specificity is obtained by mak-
ing the conservative assumption that potentially all positive results are false positive results.
This is in contrast to other studies which use a PCR-test as a reference to estimate sensitivity
and specificity of an Ag-Test [4–7].
Methods
From late October to early November 2020, Slovakia undertook large scale testing of its popu-
lation [8]. Participants were tested at specially set up locations by medical personnel via naso-
pharyngeal swab sampling and received their results after a short waiting period. For testing,
the SD Biosensor Standard Q Ag-Test was used [9, 10]. The tests in Slovakia were divided into
three phases. In the first pilot phase, testing was only conducted in certain particularly affected
counties. In Phase 2 (31.10.–1.11.) all Slovak counties were tested. In Phase 3 (6.11.–8.11.) all
heavily affected counties (those with> 0.7% prevalence during Phase 2) were tested again. In
this retrospective study, we use publicly available data on the outcome of tests in Phase 2 on
county level [11]. Participation in testing was voluntary, but it was a condition to avoid quar-
antine. Persons that were quarantined due to a previous positive PCR-test for COVID-19 or
due to being a close contact of such a person were excluded from the test.
Statistics
To derive a lower bound for the specificity we made the conservative (“worst case”) assump-
tion that potentially all positive results constitute false positive results. For each of the 79 coun-
ties, we compute the rate of positive tests together with two-sided binomial Clopper-Pearson
confidence intervals at the Bonferroni-adjusted significance level of alpha = 0.05/79 (adjusted
for the number of counties; see e.g. [12]). The minimum upper bound of these adjusted confi-
dence intervals is an upper 97.5% confidence bound for the test positivity rate. This will be in a
county with low disease activity and a large sampled population. Under the conservative
assumption that all positive results constitute false positives, it is also an upper bound on the
false positive rate of the test and defines a lower bound for the true specificity. Denoting preva-
lence, sensitivity and specificity by r, s and p, this holds under the assumption that s + p� 1
(i.e., that the probability of a positive test result is larger for a SARS-COV2 positive than for a
SARS-COV2 negative subject). This is fulfilled for any test that performs not strictly worse
than chance. Then the overall rate of positive results is given by q = r s + (1 − r)(1 − p) and it
follows that q� 1 − p, where 1 − p is the false positive rate of the test. Consequently, 1 − q is a
lower bound for the specificity p.
Results
In phase 2, all residents aged 10 to 65 throughout Slovakia were invited to get tested and 3 625
332 participated (about 66% of the population of Slovakia). Among 79 administrative counties
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of Slovakia, participation rate varied from 39% (Košice III county) to 78% (Senec county) of
inhabitants. Fig 1 depicts the test positivity rate of the individual counties ordered according
to the upper bound of the simultaneous Bonferroni adjusted 95% confidence interval from low
to high incidence. The lowest upper bound (obtained for Rožnava) is 0.40% (see Table 1). In
terms of specificity (instead of false positives) this implies that with 97.5% confidence, the spec-
ificity of Standard Q is higher than 99.6%. As a sensitivity analysis we also consider the five
counties with the lowest upper bound for the positivity rate. All imply specificities above
99.54%. These counties include regions with both relatively low participation rate (Rožňava,
Revúca and Veľký Krtı́š rank 65., 67. and 57. in participation among the 79 counties) and rela-
tively high participation rate (Bratislava IV and Bratislava III rank 13. and 4.).
Fig 1. SARS-CoV-2 antigen detected incidence in Slovakian mass testing by county. Test positivity rates among the 3 625 332 tested persons in the
79 counties with simultaneous Bonferroni adjusted 95% confidence intervals. Counties are ordered from low to high incidence by the upper confidence
bound. Data source: [11]. The corresponding data are tabled in S1 Table.
https://doi.org/10.1371/journal.pone.0255267.g001
Table 1. The five counties with the lowest upper bound on the positivity rate of antigen tests.










Rožňava 0.40% 34307 100 55% 62131
Revúca 0.41% 21419 58 54% 39537
Bratislava
IV
0.43% 65861 229 67% 97792
Bratislava
III
0.45% 49788 175 72% 69479
Veľký Krtı́š 0.46% 24282 76 56% 43263
https://doi.org/10.1371/journal.pone.0255267.t001
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Discussion
In this study the lower bound for the specificity of the SD Biosensor Standard Q AG test was
96.4%. This worst case analysis provides only a lower bound of the true specificity since it
neglects entirely the true incidence of COVID-19. As the antigen tests in Slovakia were not
controlled directly using accompanying PCR-tests, we refrain from an attempt to subdivide
the observed positives into true and false positives.
The above estimate is consistent with the information provided by the manufacturer [14],
stating 0.32% (0.01, 1.78) as a false positive rate—a very broad CI. The derived upper bound
from the mass testing is more informative and appears relevant in that it constitutes the first
(to the best of our knowledge) bound obtained from large scale practical use of Standard Q
and also suggests better performance of Standard Q compared to previous studies: a large
study (with 2347 SARS-CoV-2-free samples based on a PCR-test), suggests a specificity of
99.3% (CI 98.6–99.6) [7]. Other available specificity estimates are based on an order of magni-
tude smaller samples (99.2% (CI 97.1–99.8) [4] and 100% [6] and, in addition, are from study
populations with high incidence rates (according to PCR-testing). A point estimate of 98.53%
is given by [5], based on 100 SARS-Cov2-free samples with other respiratory viruses present
and 35 samples from healthy volunteers.
Data from Phase 2 was used in this study, because the general countrywide testing was per-
formed irrespective of regional incidence rates, covering also regions with potentially very low
incidence. The data has also been used to investigate spatial patterns of the spread of COVID-
19 [10] and to demonstrate that both mass-scale testing and restrictive measures contributed
to the sharp drop in COVID-19 incidence [9]. However, to avoid a positively biased specificity
estimate, compared to [9] we use an updated, more detailed dataset, where an erroneous posi-
tivity rate for Bratislava IV has been corrected. The binomial distribution assumption underly-
ing the computation of the Clopper-Pearson confidence intervals, is based on the assumption
of independent events that could be violated if, e.g. testing stations were operating with differ-
ent quality. However, the Bonferroni-correction is a strictly conservative approach to derive
simultaneous confidence bounds that account for the selection of the county with the lowest
upper bound to derive the estimate. It is well understood in the epidemiology literature that
imperfect reference criteria lead to a systematic bias of the true incidence [15]. Specifically, the
sensitivity and specificity of tests are systematically underestimated if the criterion (SARS--
CoV-2 infection) cannot be assessed directly and tests are compared to a surrogate criterion as
gold standard which is subject to errors. This could be a contributing factor for the relatively
higher specificity found in Slovak data compared to other studies. However, there are other
conceivable factors that could bias the results: different quality of swab sampling and handling,
low temperature in outdoor testing stations, deviations in the production over time and data
quality.
While the analysis is based on a worst case assumption, considering all positives to be false
positives, the obtained estimate appears relevant in that it constitutes the first bound obtained
from large scale practical use of Standard Q. It suggests better specificity of Standard Q com-
pared to previous studies and these findings can support the planning and justification of
future mass testing programs. Besides test specificity, the sensitivity is essential for the evalua-
tion of the overall utility of mass testing strategies. Unfortunately, based on the mass testing
data set no estimate of the test sensitivity can be obtained and, to our knowledge, no sensitivity
estimates have been provided in a mass-testing setting so far such that further studies are
needed.
PLOS ONE Analysis of the specificity of a COVID-19 antigen test in the Slovak mass testing program
PLOS ONE | https://doi.org/10.1371/journal.pone.0255267 July 29, 2021 4 / 6
Supporting information
S1 Table. County, number of tests, number of positive tests, positivity rates, simultaneous
Bonferroni adjusted 95% confidence intervals, and standard errors of the positivity rates
in the 79 counties. Counties are ordered from low to high incidence by the upper confidence
bound. Data source [11].
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